Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Aug 2005Cited by 55 (Europe PMC)

PMID16005252DOI10.1016/j.ghir.2005.05.002PepBankPUB-16005252

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 (mecasermin).

01HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome
In insulin-treated type 2 diabetes, rhIGF-I/rhIGFBP-3 reduced insulin requirements by 54% to 82% across four regimens.
In plain wordsIn type 2 diabetes, the complex reduced insulin requirements across four regimens.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseInsulin requirements
Study
n = 52
Outcome group
Glycemic control · Metabolic and weight
Measurements
Insulin requirement decrease
54 to 82%
across the four dosage groups
Source sentences
Summary
Across these four groups rhIGF-I/rhIGFBP-3 decreased insulin requirements between 54% and 82%.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525201
02HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome
In insulin-treated type 2 diabetes, fasting glucose decreased by 32-37% during rhIGF-I/rhIGFBP-3 treatment.
In plain wordsIn type 2 diabetes, fasting glucose decreased during complex treatment.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFasting glucose
Study
n = 52
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting glucose decrease
32 to 37%
across the four dosage groups
Source sentences
Summary
Fasting glucose decreased by 32-37%.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525202
03HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome
In insulin-treated type 2 diabetes, mean daily glucose decreased by 9-23% across all rhIGF-I/rhIGFBP-3 groups.
In plain wordsIn type 2 diabetes, daily glucose decreased in all complex treatment groups.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseMean daily blood glucose
Study
n = 52
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean daily blood glucose decrease
9 to 23%
range across the four groups
Source sentences
Summary
Mean daily blood glucose (4 determinations per day) declined in all 4 groups (range 9-23% decrease).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525203
04HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialPharmacokinetics
In type 2 diabetes, total IGF-I rose 4.0-4.8-fold and peaked at 16-24 h during complex treatment.
In plain wordsIn type 2 diabetes, the complex increased total IGF-I concentrations.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePeak total IGF-I
Study
n = 52
Outcome group
Pharmacokinetics · Endocrine and hormones
Measurements
Peak total IGF-I increase
4 to 4.8 fold
peak total IGF-I
Time of peak total IGF-I
16 to 24 h
peak total IGF-I
Source sentences
Summary
The peak total IGF-I values were increased to 4.0-4.8-fold at 16-24 h.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525204
05HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialPharmacokinetics
In type 2 diabetes, free IGF-I rose 7.1 to 8.2-fold and peaked at 16-20 h after complex administration.
In plain wordsIn type 2 diabetes, the complex increased free IGF-I concentrations.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePeak free IGF-I
Study
n = 52
Outcome group
Pharmacokinetics · Endocrine and hormones
Measurements
Peak free IGF-I increase
7.1 to 8.2 fold
free IGF-I
Time of peak free IGF-I
16 to 20 h
after administration
Source sentences
Summary
For free IGF-I the increase varied between 7.1 and 8.2-fold and peak values were attained at 16-20 h after administration.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525205
06HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialPharmacokinetics
In type 2 diabetes, free IGF-I Tmax with the complex was lower than in published lower-dose IGF-I-alone studies.
In plain wordsIn type 2 diabetes, the complex produced an earlier free IGF-I peak than published IGF-I-alone studies.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFree IGF-I Tmax
Study
n = 52
Comparator
Previously published IGF-I-alone studies
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Both the time to maximum concentration (Tmax) and the maximum free IGF-I levels (Cmax) on day 1 for all groups were substantially less than previously published studies, wherein lower doses of rhIGF-I were given without IGFBP-3.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525206
07HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialPharmacokinetics
In type 2 diabetes, free IGF-I Cmax with the complex was lower than in published lower-dose IGF-I-alone studies.
In plain wordsIn type 2 diabetes, the complex produced a lower free IGF-I peak than published IGF-I-alone studies.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFree IGF-I Cmax
Study
n = 52
Comparator
Previously published IGF-I-alone studies
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Both the time to maximum concentration (Tmax) and the maximum free IGF-I levels (Cmax) on day 1 for all groups were substantially less than previously published studies, wherein lower doses of rhIGF-I were given without IGFBP-3.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525207
08HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialSafety outcome
In type 2 diabetes, side effects of rhIGF-I plus rhIGFBP-3 occurred at 4%, less often than reported in previous studies of IGF-I without IGFBP-3.
In plain wordsIn type 2 diabetes, side effects were less frequent with IGF-I plus IGFBP-3 than in earlier studies of IGF-I alone.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseSide effect frequency
Study
n = 52
Comparator
Previously published IGF-I-alone studies
Outcome group
Adverse events · Whole body
Measurements
Frequency of side effects such as edema, jaw pain and arthralgias
4%
combined frequency, rhIGF-I plus rhIGFBP-3
Source sentences
Summary
The frequency of side effects such as edema, jaw pain and arthralgias was 4% which is less than that has been reported in previous studies wherein IGF-I was administered without IGFBP-3.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525214
09HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome
In insulin-treated type 2 diabetes, glucose improvement with rhIGF-I plus rhIGFBP-3 was greatest in dosage regimen groups 2 and 3.
In plain wordsIn type 2 diabetes, glucose improved most in dosage groups 2 and 3 of the IGF-I and IGFBP-3 treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableGlucose improvement across regimens
Study
n: not reported in source
Comparator
Other dosage regimens
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The improvement in glucose values and the degree of reduction in insulin requirement were the greatest in groups 2 and 3 and the patients in those groups had the highest free IGF-I levels.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525208
10HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialEfficacy outcome
In insulin-treated type 2 diabetes, the reduction in insulin requirement with rhIGF-I plus rhIGFBP-3 was greatest in dosage regimen groups 2 and 3.
In plain wordsIn type 2 diabetes, insulin needs fell most in dosage groups 2 and 3 of the IGF-I and IGFBP-3 treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableInsulin reduction across regimens
Study
n: not reported in source
Comparator
Other dosage regimens
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The improvement in glucose values and the degree of reduction in insulin requirement were the greatest in groups 2 and 3 and the patients in those groups had the highest free IGF-I levels.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525209
11HumanNot a test of IGF-1 (mecasermin) aloneNon-randomized trialPharmacokinetics
In insulin-treated type 2 diabetes, dosage regimen groups 2 and 3 of rhIGF-I plus rhIGFBP-3 had the highest free IGF-I levels.
In plain wordsIn type 2 diabetes, free IGF-I was highest in dosage groups 2 and 3 of the IGF-I and IGFBP-3 treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseFree IGF-I across regimens
Study
n: not reported in source
Comparator
Other dosage regimens
Outcome group
Pharmacokinetics · Endocrine and hormones
Source sentences
Summary
The improvement in glucose values and the degree of reduction in insulin requirement were the greatest in groups 2 and 3 and the patients in those groups had the highest free IGF-I levels.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 52 patients with insulin-treated type 2 diabetes received recombinant human IGF-I plus rhIGFBP-3 in one of four dosage regimens for 14 days.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-1600525210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.